Psoriasis (Ps) and psoriatic arthritis (PsA): combination biologic therapy reports.
| No. Patients | Diagnosis | Combination Therapy | Dose | Reason to Start Combination Therapy | Followup | SAE | |
|---|---|---|---|---|---|---|---|
| Lowes18 | 1 | Ps | Efalizumab + infliximab | 125 mg QW + 400 mg 0.2 Q6W | Recurrent psoriasis | 4 mo | None |
| Hamilton20 | 20 | PsA | Efalizumab + etanercept/infliximab | 1 mg/kg QW+ 25/50 mg QW or 5–6 mg/kg | Patients with Ps and PsA | NA | None |
| Adisen19 | 1 | PsA | Efalizumab + etanercept | 1 mg/kg QW+ 50 mg QW | Ps and PsA (efalizumab for skin, etanercept for joint) | 6 wks | None |
| Kitamura21 | 1 | PsA | Efalizumab + etanercept | 80 mg QW+ 50 mg QW | Recalcitrant Ps and PsA unresponsive to conventional treatment | 1 yr | TB |
| Cuchacovich, et al, 2011 | 1 | PsA | Ustekinumab + etanercept | 90 mg 0.4 Q4W + 50 mg QW | Ps and PsA unresponsive to 1 biologic agent alone | > 1 yr | None |
QW: once a week; SAE: serious adverse events; TB: tuberculosis; NA: not available.